In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...
CEO Sean Bohen outlined the company’s focus on advancing endocrine therapies for ER-positive, HER2-negative breast cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results